Developer docs
API playgroundTry for free, no card

Search company profiles

VivoSim Labs

Full company profile

uuid0004yi6

Namestring
VivoSim Labs
Legal namestring
VivoSim Labs, Inc.
Websiteurl
vivosim.ai
Company typeenum
Public
Founded yearint
2007
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D tissue models, preclinical toxicology testing, drug-induced liver injury, human-relevant safety assessment, NAM-based drug screening
Industry1 code
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Preclinical Toxicology Testing Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Toxicology Testing Services
TypeProfessional Services
Description

VivoSim Labs generates revenue through contracted toxicology testing services using NAMkind™ 3D liver and intestine models. Services include prospective screens (20+ compounds in 2 weeks), translational bridge studies, and investigative toxicology (1-2 compounds across multiple concentrations with 4-week turnaround). Standard liver service screens 36-40 compounds at 4 concentrations each with 17-day treatment period; GI service tests 30 compounds with 7-day exposure protocol.

vivosim.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1Prospective Toxicity Screens
ModelOtherBilling cadenceMulti-year contract
Notes

Quick screen service: 20+ compounds screened in 2 weeks using core biomarkers. Liver service: 36-40 compounds at 4 concentrations each with 6 replicates per concentration over 17-day treatment period.

vivosim.ai
2Translational Risk Bridge
ModelOtherBilling cadenceMulti-year contract
Notes

Species-specific models plus optional mechanistic panels (inflammatory markers Luminex, gene expression RNAseq, proteomics) for confirmation of human relevance and regulatory-ready narratives.

vivosim.ai
3Investigative Toxicology
ModelOtherBilling cadenceMulti-year contract
Notes

On-demand service for unexpected findings: 1-2 compounds across multiple concentrations, 4-week turnaround with mechanistic insights.

vivosim.ai
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1NAMkind
Description

3D human tissue models including liver and intestine models for toxicology testing and drug development.

vivosim.ai
Core offering1 text field

VivoSim Labs develops NAMkind™ 3D human liver and intestinal tissue models built from primary human cells (hepatocytes, Kupffer cells, endothelial and stellate cells for liver; epithelial and stromal cells for intestine) and delivers contracted toxicology testing services using these models. The offerings include prospective compound screens, translational bridge studies with species-specific variants, and on-demand investigative toxicology, all aligned with FDA's New Approach Methodology (NAM) framework to provide human-relevant safety data for pharmaceutical and biotech drug development pipelines.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

VivoSim Labs offers a unified portfolio of NAMkind™ 3D human tissue models and associated toxicology testing services. The core products include the NAMkind™ Liver Model (3D liver spheroids with hepatocytes, Kupffer cells, endothelial, and stellate cells) and the NAMkind™ Intestine Model (3D Transwell platform with epithelial and stromal cells). These models are offered alongside three service tiers: Liver Toxicology Services (standard screening of up to 40 compounds over 17 days), Gastrointestinal Toxicology Services (intestinal barrier assessment over 7 days with TEER and viability readouts), and Investigative Toxicology Services (mechanistic studies for at-risk compounds in 4 weeks). All offerings are aligned with FDA's New Approach Methodology (NAM) framework and leverage primary human cells to provide human-relevant safety data for drug development.

Product and service3 records
1Liver Toxicology Services
CategoryToxicology Testing Services
Description

Contracted toxicology testing service using the NAMkind™ Liver Model that screens up to 40 compounds at multiple concentrations over a 17-day treatment period, measuring viability, functional output, and DILI biomarkers (LDH release, albumin secretion, ATP viability, glutathione status). Includes optional mechanistic panels and species-specific variants (rat, mouse, dog, monkey). Designed for pharmaceutical and biotech teams during Hit-to-Lead, Lead Optimization, and Candidate Nomination.

2Gastrointestinal Toxicology Services
CategoryToxicology Testing Services
Description

Full-service intestinal toxicity testing using the NAMkind™ Intestine Model. Tests up to 30 compounds over a 7-day exposure protocol at four concentrations, assessing barrier function (TEER), cell viability (ATP, Alamar Blue), and histological changes with a 4-week turnaround. Targets pharmaceutical and biotech programs with high GI toxicity risk such as oncology and IBD.

3Investigative Toxicology Services
CategoryToxicology Testing Services
Description

On-demand mechanistic toxicology service using BioPrint 3D human tissue models to investigate unexpected compound-related toxicity signals. Supports 1-2 compounds across multiple concentrations with a 4-week turnaround, providing insights into cellular stress, tissue damage, and inflammatory signaling to support go/modify/stop decisions.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1JCBio
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Korean distribution partner for VivoSim products. Ensures hassle-free buying experience for customers in Korea. Listed on distributors page of VivoSim website alongside Tekon.

vivosim.ai
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Chinese distribution partner (Tekon Biotech) for VivoSim products. Enables local access for customers in China. Listed alongside JCBio as regional distribution partners.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Commercial-stage organ-on-chip company with Liver-Chip and Intestine-Chip products used by major pharma for preclinical safety assessment. Comparable to VivoSim's NAMkind portfolio in tissue types and target customers, though with a more capital-intensive chip platform.

TypeBroad incumbent
Description

Global CRO with a large preclinical toxicology practice, including emerging NAM offerings. Represents an incumbent competitor and potential partner for VivoSim's NAMkind services.

TypeDirect peer
Description

Offers OrganoPlate-based 3D tissue models and organ-on-chip toxicology screening services for pharmaceutical customers. Comparable to VivoSim on the technology axis (microfluidic 3D human tissue models) and the services business model.

TypeDirect peer
Description

Provider of 3D in vitro microtissue organoid models (liver, pancreas, etc.) for predictive toxicology and disease modeling. Closely comparable to VivoSim's NAMkind Liver platform in terms of primary-cell-based 3D spheroid technology and target customer base.

TypeBroad incumbent
Description

Preclinical CRO offering toxicology, safety pharmacology, and research models. Comparable as an established alternative to VivoSim for outsourced preclinical toxicology studies.

TypeEmerging player
Description

Developer of multi-organ-chip microphysiological systems for toxicology and efficacy testing. Comparable to VivoSim as a NAM-focused tissue model company serving pharma R&D.

TypeDirect peer
Description

Leading contract research organization specializing in in vitro and in silico ADME-Tox services, including liver and intestinal toxicity assays. Directly comparable to VivoSim as a commercial in vitro toxicology services provider for pharma and biotech.

TypeBroad incumbent
Description

Supplier of primary human cells and in vitro test systems, including hepatocytes used in liver toxicology workflows. Comparable to VivoSim as a supplier into the human-relevant in vitro toxicology market, with potential partnership and overlap.

9CN Bio
TypeDirect peer
Description

Developer of organ-on-chip and microphysiological systems, including liver and gut models for drug safety and efficacy testing. Direct peer to VivoSim in the NAM-based 3D tissue model space serving pharma preclinical safety applications.

TypeBroad incumbent
Description

Large preclinical CRO with extensive in vivo and in vitro toxicology service lines serving global pharma. Competes with VivoSim for preclinical safety spend and represents both a competitive threat and a potential partnership/buyer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VivoSim Labs

Preclinical Toxicology Testing Servicesvivosim.ai

VivoSim Labs firmographics

Firmographics
Name
VivoSim Labs
Legal name
VivoSim Labs, Inc.
Website
https://vivosim.ai
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

VivoSim Labs industry classification

Industry
Product category
Preclinical Toxicology Testing Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • 3D tissue models
  • Preclinical toxicology testing
  • Drug-induced liver injury
  • Human-relevant safety assessment
  • NAM-based drug screening

Where VivoSim Labs is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

VivoSim Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Toxicology Testing Services: VivoSim Labs generates revenue through contracted toxicology testing services using NAMkind™ 3D liver and intestine models. Services include prospective screens (20+ compounds in 2 weeks), translational bridge studies, and investigative toxicology (1-2 compounds across multiple concentrations with 4-week turnaround). Standard liver service screens 36-40 compounds at 4 concentrations each with 17-day treatment period; GI service tests 30 compounds with 7-day exposure protocol.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProspective Toxicity Screens
OtherMulti-year contractTranslational Risk Bridge
OtherMulti-year contractInvestigative Toxicology

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

VivoSim Labs product offering

Product offering

Core offering

VivoSim Labs develops NAMkind™ 3D human liver and intestinal tissue models built from primary human cells (hepatocytes, Kupffer cells, endothelial and stellate cells for liver; epithelial and stromal cells for intestine) and delivers contracted toxicology testing services using these models. The offerings include prospective compound screens, translational bridge studies with species-specific variants, and on-demand investigative toxicology, all aligned with FDA's New Approach Methodology (NAM) framework to provide human-relevant safety data for pharmaceutical and biotech drug development pipelines.

Product overview

VivoSim Labs offers a unified portfolio of NAMkind™ 3D human tissue models and associated toxicology testing services. The core products include the NAMkind™ Liver Model (3D liver spheroids with hepatocytes, Kupffer cells, endothelial, and stellate cells) and the NAMkind™ Intestine Model (3D Transwell platform with epithelial and stromal cells). These models are offered alongside three service tiers: Liver Toxicology Services (standard screening of up to 40 compounds over 17 days), Gastrointestinal Toxicology Services (intestinal barrier assessment over 7 days with TEER and viability readouts), and Investigative Toxicology Services (mechanistic studies for at-risk compounds in 4 weeks). All offerings are aligned with FDA's New Approach Methodology (NAM) framework and leverage primary human cells to provide human-relevant safety data for drug development.

Differentiator

Problem solved

Functional benefit

Brands

  • NAMkind: 3D human tissue models including liver and intestine models for toxicology testing and drug development.

Products and services

  • Liver Toxicology Services Contracted toxicology testing service using the NAMkind™ Liver Model that screens up to 40 compounds at multiple concentrations over a 17-day treatment period, measuring viability, functional output, and DILI biomarkers (LDH release, albumin secretion, ATP viability, glutathione status). Includes optional mechanistic panels and species-specific variants (rat, mouse, dog, monkey). Designed for pharmaceutical and biotech teams during Hit-to-Lead, Lead Optimization, and Candidate Nomination.
  • Gastrointestinal Toxicology Services Full-service intestinal toxicity testing using the NAMkind™ Intestine Model. Tests up to 30 compounds over a 7-day exposure protocol at four concentrations, assessing barrier function (TEER), cell viability (ATP, Alamar Blue), and histological changes with a 4-week turnaround. Targets pharmaceutical and biotech programs with high GI toxicity risk such as oncology and IBD.
  • Investigative Toxicology Services On-demand mechanistic toxicology service using BioPrint 3D human tissue models to investigate unexpected compound-related toxicity signals. Supports 1-2 compounds across multiple concentrations with a 4-week turnaround, providing insights into cellular stress, tissue damage, and inflammatory signaling to support go/modify/stop decisions.

Companies that use VivoSim Labs

Customer profile

Segments3 records

Ideal customer profiles3 records

VivoSim Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

VivoSim Labs partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered regional.

  • JCBioregionalChannel Partner/ Reseller/ DistributorKorean distribution partner for VivoSim products. Ensures hassle-free buying experience for customers in Korea. Listed on distributors page of VivoSim website alongside Tekon.
  • TekonregionalChannel Partner/ Reseller/ DistributorChinese distribution partner (Tekon Biotech) for VivoSim products. Enables local access for customers in China. Listed alongside JCBio as regional distribution partners.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

VivoSim Labs competitors and assessment

Company assessment

Emerging players

  • Emulate: Commercial-stage organ-on-chip company with Liver-Chip and Intestine-Chip products used by major pharma for preclinical safety assessment. Comparable to VivoSim's NAMkind portfolio in tissue types and target customers, though with a more capital-intensive chip platform.
  • TissUse: Developer of multi-organ-chip microphysiological systems for toxicology and efficacy testing. Comparable to VivoSim as a NAM-focused tissue model company serving pharma R&D.

Broad incumbents

  • Labcorp Drug Development (formerly Covance): Global CRO with a large preclinical toxicology practice, including emerging NAM offerings. Represents an incumbent competitor and potential partner for VivoSim's NAMkind services.
  • Inotiv: Preclinical CRO offering toxicology, safety pharmacology, and research models. Comparable as an established alternative to VivoSim for outsourced preclinical toxicology studies.
  • BioIVT: Supplier of primary human cells and in vitro test systems, including hepatocytes used in liver toxicology workflows. Comparable to VivoSim as a supplier into the human-relevant in vitro toxicology market, with potential partnership and overlap.
  • Charles River Laboratories: Large preclinical CRO with extensive in vivo and in vitro toxicology service lines serving global pharma. Competes with VivoSim for preclinical safety spend and represents both a competitive threat and a potential partnership/buyer.

Direct peers

  • MIMETAS: Offers OrganoPlate-based 3D tissue models and organ-on-chip toxicology screening services for pharmaceutical customers. Comparable to VivoSim on the technology axis (microfluidic 3D human tissue models) and the services business model.
  • InSphero: Provider of 3D in vitro microtissue organoid models (liver, pancreas, etc.) for predictive toxicology and disease modeling. Closely comparable to VivoSim's NAMkind Liver platform in terms of primary-cell-based 3D spheroid technology and target customer base.
  • Cyprotex (an Evotec company): Leading contract research organization specializing in in vitro and in silico ADME-Tox services, including liver and intestinal toxicity assays. Directly comparable to VivoSim as a commercial in vitro toxicology services provider for pharma and biotech.
  • CN Bio: Developer of organ-on-chip and microphysiological systems, including liver and gut models for drug safety and efficacy testing. Direct peer to VivoSim in the NAM-based 3D tissue model space serving pharma preclinical safety applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VivoSim Labs social profiles

Digital presence

VivoSim Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VivoSim Labs leadership team

Management profile

Number of profiles

Profiles4 records

VivoSim Labs funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VivoSim Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VivoSim Labs

What does VivoSim Labs do?

VivoSim Labs develops NAMkind™ 3D human liver and intestinal tissue models built from primary human cells (hepatocytes, Kupffer cells, endothelial and stellate cells for liver; epithelial and stromal cells for intestine) and delivers contracted toxicology testing services using these models. The offerings include prospective compound screens, translational bridge studies with species-specific variants, and on-demand investigative toxicology, all aligned with FDA's New Approach Methodology (NAM) framework to provide human-relevant safety data for pharmaceutical and biotech drug development pipelines.

Is VivoSim Labs a public or private company?

VivoSim Labs is a public company. It is classified as public and is currently operating.

When was VivoSim Labs founded?

VivoSim Labs was founded in 2007. It employs 11 to 50 people.

Where is VivoSim Labs based?

VivoSim Labs is headquartered in San Diego, United States, in the North America region.

How does VivoSim Labs make money?

One revenue line is on record: toxicology Testing Services.

Who are VivoSim Labs's main competitors?

Emerging players on record are Emulate and TissUse. Broad incumbents are Labcorp Drug Development (formerly Covance), Inotiv, BioIVT and Charles River Laboratories. Direct peers are MIMETAS, InSphero, Cyprotex (an Evotec company) and CN Bio.

Does VivoSim Labs have an API?

No public API is recorded for VivoSim Labs.

What industry is VivoSim Labs in?

VivoSim Labs's product category is Preclinical Toxicology Testing Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanVivoSim to Present 3D Safety Data at Toxicology MeetingVivoSim Labs will present two scientific posters at the ACT 47th Annual Meeting in San Antonio, Texas, on November 15–18, 2026. The posters showcase multiparametric 3D human tissue data for DILI risk stratification and gastrointestinal toxicity profiling, claiming superior predictive power over cell death alone.American Banking and Market NewsVivoSim Labs (NASDAQ:VIVS) and Maravai LifeSciences (NASDAQ:MRVI) Critical ReviewMaravai LifeSciences beats VivoSim Labs on 11 of 15 factors, including institutional ownership, valuation, and analyst ratings. Maravai has higher revenue ($185.74M vs $112M) and a lower P/E ratio, while VivoSim's beta is 1.58 versus Maravai's 0.61. Analysts rate Maravai more favorably with a consensus price target of $7.38.FinancialContent Business Page3 Stocks Under $1: INO, VIVS, FNUC in Focus for NovemberINOVIO, VivoSim Labs, and Frontier Nuclear and Minerals closed below $1 on October 30, with prices of $0.60, $0.15, and $0.73. INOVIO received FDA accelerated approval for VOCERYQ, VivoSim expanded its tissue-model services, and Frontier's uranium drilling program targets a resource estimate by early 2027.TradingViewVivoSim Labs, Inc. (VIVS) Partners With Chemveda to Screen AI-Designed DrugsVivoSim Labs and Chemveda will combine compound design, synthesis, and screening in VivoSim's human liver and intestine tissue models. The joint offering is expected to launch in Q4 2026, with no financial terms disclosed. Screens can assess over 20 compounds in two weeks.Business & Financial3 Stocks Under $1: INO, VIVS, FNUC In Focus For NovemberINOVIO, VivoSim Labs, and Frontier Nuclear and Minerals closed below $1 on October 30, with prices of $0.60, $0.15, and $0.73. INOVIO received FDA accelerated approval for VOCERYQ, VivoSim expanded its human tissue testing services, and Frontier announced a 2026 drilling program for its Pine Ridge uranium project.American Banking and Market NewsIllumina (NASDAQ:ILMN) vs. VivoSim Labs (NASDAQ:VIVS) Head-To-Head ComparisonIllumina outperforms VivoSim Labs on 11 of 13 comparison factors, including revenue, earnings, and analyst ratings. Illumina's consensus price target is $234.41, implying a 13.51% upside, while VivoSim Labs trades at a lower P/E but carries higher volatility and losses.TradingViewVivoSim Labs, Inc. (VIVS) Expands Into Human Disease Efficacy TestingVivoSim Labs expanded its NAMkind platform beyond toxicology to include patient-derived liver and intestinal disease models for efficacy testing and biomarker profiling. The company claims the new services could more than double its total addressable market, with a catalyst being disclosed contracts or revenue contribution.American Banking and Market NewsReviewing VivoSim Labs (NASDAQ:VIVS) & Charles River Laboratories International (NYSE:CRL)Charles River Laboratories International beats VivoSim Labs on 10 of 14 factors, including profitability and analyst ratings. Charles River trades at a lower P/E ratio and has a consensus target price of $302.33, while VivoSim Labs is more volatile and has a lower rating score.Defense WorldVivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head ComparisoniSpecimen and VivoSim Labs are compared on analyst ratings, ownership, profitability, and valuation. iSpecimen beats VivoSim Labs on 9 of 11 factors, with higher revenue and earnings, but VivoSim Labs trades at a lower price-to-earnings ratio.Ticker ReportComparing VivoSim Labs (NASDAQ:VIVS) and iSpecimen (NASDAQ:ISPC)iSpecimen beats VivoSim Labs on 9 of 11 factors, including higher revenue and lower price-to-earnings ratio. VivoSim Labs has a beta of 1.45 versus iSpecimen's 1.62, and iSpecimen has higher institutional ownership at 13.6% versus 8.2%.